Nowadays, treatments targeting the aberrant vascular endothelial growth factor/receptor (VEGF/VEGFR) pathway and/or immune checkpoint inhibitors are among the main and most effective therapy for ccRCC. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.